Skip to main content
. 2005 Dec 21;103(1):57–62. doi: 10.1073/pnas.0609973103

Fig. 1.

Fig. 1.

17-AAG selectively inhibits A-Raf and C-Raf but not WT B-Raf expression. (A) SK-Mel-31 cells (WT B-Raf) were treated with the indicated concentrations of 17-AAG for 24 h, and levels of A-Raf, B-Raf, C-Raf (Raf-1), and p85 PI3-kinase expression were determined by immunoblotting. 17-AAG caused a dose-dependent decline in A-Raf and C-Raf expression but had no effect on expression of WT B-Raf. (B)(Left) 17-AAG had no effect on the expression of WT B-Raf in a panel of melanoma, colon, and breast cancer cells. (Right) p85 PI3-kinase expression was assessed as a loading control.